ストックスクリーナーアプリを入手
2.05
7.66%
-0.17
プレマーケット:
2.06
0.01
+0.49%
Esperion Therapeutics Inc (ESPR) 最新ニュース
Needham Maintains Esperion Therapeutics(ESPR.US) With Buy Rating, Maintains Target Price $5 - Moomoo
Esperion Therapeutics, Inc. (ESPR) Latest Stock News & Headlines - Yahoo Finance
Esperion Therapeutics Highlights 38% Revenue Growth, Enbumyst Launch Plan at Needham Conference - Yahoo Finance
Personalized treatments advance as Esperion Therapeutics urges broader use of hsCRP in heart care - Traders Union
Esperion Therapeutics, Inc. (ESPR) latest stock news and headlines - Yahoo Finance Singapore
Esperion Therapeutics (ESPR) Down 10% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Esperion (ESPR) highlights inclusion of bempedoic acid in 2026 ACC/AHA dyslipidemia guidelines - MSN
Guidance Update: What is the next catalyst for Esperion Therapeutics Inc2026 Drop Watch & Reliable Breakout Stock Forecasts - baoquankhu1.vn
Movement Recap: What are Esperion Therapeutics Incs technical support levels2026 Price Targets & Weekly Return Optimization Alerts - baoquankhu1.vn
ESPR Forecast, Price Target & Analyst Ratings | ESPERION THERAPEUTICS INC (NASDAQ:ESPR) - ChartMill
Esperion Therapeutics Stock Dips After Q4 Earnings Miss Expectations - StocksToTrade
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Ann Arbor pharmaceutical company acquires nasal spray treatment manufacturer - MLive.com
Esperion Therapeutics, Inc. $ESPR Shares Purchased by JPMorgan Chase & Co. - MarketBeat
This Cheap $2.60's Stock Is A Great Investment With Huge Guideline News. Top 3 Analysts Say Strong Buy $9 to $16 - Moomoo
ESPR Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Esperion Therapeutics, Inc. (ESPR) stock price, news, quote and history - Yahoo Finance UK
Esperion Completes Corstasis Acquisition, Expands Cardiovascular Portfolio - The Globe and Mail
Esperion sells Japan royalty rights for $50 million to Athyrium By Investing.com - Investing.com Canada
Esperion Therapeutics Closes Acquisition of Corstasis Therapeutics, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray) - Sahm
Athyrium Capital Management and Esperion Enter Into $50 Million Japan Royalty Financing to Support Strategic Acquisition of Corstasis Therapeutics - The Manila Times
Athyrium Capital Management and Esperion Therapeutics Inc. (NASDAQ: ESPR) have signed a Japanese royalty financing agreement worth $50 million - Bitget
Esperion Therapeutics Enters First Amendment To Credit Agreement On April 2, 2026SEC Filing - TradingView — Track All Markets
Esperion Therapeutics, Athyrium Capital Management Sign $50 Million Japan Royalty Financing - marketscreener.com
Esperion Therapeutics Inc. has successfully secured financing, which will be specifically used to support its acquisition of Corstasis Therapeutics. - Bitget
Esperion Therapeutics Inc. (ESPR) has entered into a new financial arrangement with the Athyrium Fund. - Bitget
Esperion Adds $25 Million Term Loans, Sells $50 Million Otsuka Royalties to Fund Corstasis Buy - TradingView — Track All Markets
Esperion (ESPR) acquires Corstasis, adds $25M term loan and $50M royalty sale - Stock Titan
Esperion sells Japan royalty rights for $50 million to Athyrium - Investing.com
Esperion completes acquisition of Corstasis Therapeutics - Investing.com
Athyrium Capital Management and Esperion Enter Into $50 - GlobeNewswire
Esperion Therapeutics ranks 88 among 300 on Americas Fastest Growing Companies list - Traders Union
Zacks Research Has Negative Forecast for ESPR Q2 Earnings - MarketBeat
Esperion Therapeutics Closes Acquisition of Corstasis Therapeutics, Expanding Its Cardiovascular Franchise with Enbumyst (bumetanide nasal spray) - Bitget
Esperion Presents New Data from CLEAR Outcomes Highlighting Value of Bempedoic Acid at ACC.26 - dicardiology.com
Esperion Therapeutics, Inc. completed the acquisition of Corstasis Therapeutics Inc. - marketscreener.com
New Analyst Updates: $9 and $16 Price Targets on Esperion Therapeutics Signal Major Upside From $2.63 - Moomoo
Q4 EPS Estimate for Esperion Therapeutics Raised by Analyst - MarketBeat
Athyrium Capital Management and Esperion Enter Into $50 Million Japan Royalty Financing - citybiz
Esperion Therapeutics Inc (ESPR) strengthens business outlook amid strategic agreements - MSN
Esperion to Participate in 25th Annual Needham Virtual Healthcare Conference - Bitget
Esperion to acquire Corstasis for $75M upfront payment - MSN
Esperion Therapeutics (NASDAQ:ESPR) Trading Up 9.7%Here's What Happened - MarketBeat
H.C. Wainwright Maintains Esperion Therapeutics(ESPR.US) With Buy Rating, Maintains Target Price $16 - Moomoo
Investors can watch Esperion at Needham's virtual healthcare event - Stock Titan
US Market Wrap: Can Esperion Therapeutics Inc outperform under higher oil prices2026 Technical Overview & Free Community Consensus Stock Picks - baoquankhu1.vn
Needham Virtual Healthcare Conference features Esperion Therapeutics at 25th anniversary session - Traders Union
Esperion reports bempedoic acid cut ischemic stroke risk by 22% - Investing.com Canada
Esperion Showcases New Data from CLEAR Outcomes Highlighting Value of NEXLETOL (bempedoic acid) at the American College of Cardiology's Annual Scientific Session 2026 - Bitget
Esperion Therapeutics unveils new CLEAR Outcomes data on NEXLETOL at ACC Annual Scientific Session - Traders Union
Esperion Showcases New Data from CLEAR Outcomes - GlobeNewswire
Esperion Showcases New Data from CLEAR Outcomes Highlighting Value of NEXLETOL® (bempedoic acid) at the American College of Cardiology’s Annual Scientific Session 2026 - Yahoo Finance
1.06%
1.05%
大文字化:
|
ボリューム (24 時間):